Skip to main content

Table 2 Baseline profile, infected ORIF constructs only

From: Duration of antibiotic treatment and risk of recurrence after surgical management of orthopaedic device infections: a multicenter case-control study

Variable Cases Controls p
n 31 53  
Median age, years (IQR) 55 (45–61) 51 (37–67) 0.849
Gender, n (%)    0.706
 Male 20 (65) 32 (60)  
 Female 11 (35) 21 (40)  
Median BMI (IQR) 26.4 (24.2–32.4) 26.9 (23.8–30.3) 0.513
Smoker, n (%) 12 (39) 18 (34) 0.661
Diabetes mellitus, n (%) 3 (10) 4 (8) 0.733
ASA status, n (%)
 1 6 (19) 11 (21) 0.890
 2 16 (52) 28 (53)  
  ≥ 3 7 (23) 12 (23)  
 unknown 2 (6) 2 (4)  
Infection site    0.487
 Lower leg 26 (84) 41 (77)  
 Femur 2 (6) 8 (15)  
 Upper extremity 3 (10) 4 (8)  
Additional IM nail, n (%) 2 (6) 7 (13) 0.334
Microbiology, n (%)
 MSSA 21 (68) 24 (45) 0.046
 MRSA 3 (10) 3 (6) 0.490
 CNS 2 (6) 11 (21) 0.080
 Enterococci 3 (10) 12 (23) 0.134
 Streptococci 3 (10) 3 (6) 0.490
 E. coli 1 3  
 Enterobacter spec. 3 2  
 Corynebacter spec. 1 1  
 Proteus spec. 0 1  
 Pseudomonas spec. 2 2  
 Peptostreptococci 0 3  
 Klebsiella spec. 0 2  
 Candida spec. 0 1  
Local gentamicin, n (%) 6 (19) 10 (19) 0.956
Systemic antibiotics, n (%)
 Fluoroquinolones 13 (42) 23 (43) 0.896
 Rifampicin 8 (26) 15 (28) 0.805
 Cefuroxime 6 (19) 14 (26) 0.463
 Aminopenicillins 9 (29) 9 (17) 0.194
 Clindamycin 2 (6) 5 (9) 0.633
 Linezolid 1 1  
 Vancomycin 0 2  
 Gentamicin 0 2  
 Imipenem 1 1  
 Tazobactam 1 2  
Combined fluoroquinolones and rifampicin
 None 29 (55) 18 (58)  
 Any 10 (19) 5 (16)  
 Fluoroquinolones and / or rifampicin 14 (26) 8 (26)  
  1. IQR interquartile range, BMI Body Mass Index, ASA American Society of Anesthesiologists physical status classification system, MSSA methicillin-sensitive staphylococcus aureus spec, MRSA methicillin-resistant staphylococcus aureus spec, CNS coagulase-negative staphylococci